A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts
We have previously shown that repeated sequential administration of doxorubicin, followed 24 h later by zoledronic acid, inhibits tumour growth in models of established breast cancer bone metastasis. As breast cancer patients only receive zoledronic acid every 3–4 weeks, the aim of the current study...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Elsevier
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723328/ |